Leadership changes continue at the U.S. Food and Drug Administration (FDA), with more high-level departures after FDA Commissioner Marty Makary’s exit. The effect of these changes remains to be seen, but pro-life advocates hope the personnel shake-up will also shake loose the stalled review of a Biden-era policy that removed critical safeguards around the use of mifepristone, the chemical abortion drug.
At least three high-ranking FDA officials have departed since Makary’s sudden resignation last Tuesday. Acting Director of the Center for Drug Evaluation and Research (CDER) Tracy Beth Høeg refused to sign a letter of resignation and was subsequently fired. Høeg was the fifth acting director of CDER during the second Trump administration (acting officials can serve no longer than 210 days in positions requiring Senate confirmation) and was influential in altering the FDA’s recommended immunization schedule, a policy change now blocked in federal court.
Read Full Article: https://www.lifenews.com/2026/05/20/pro-life-americans-hope-new-fda-leaders-will-finally-stop-mail-order-abortions/
